LI
EBS icon

Leap Investments’s Emergent Biosolutions EBS Stock Holding History

Leap Investments’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,100
Closed -$545K – 413
2019
Q4 		$545K Sell
10,100
-17,500
-63% -$949K 0.26% 130
2019
Q3 		$1.44M Buy
+27,600
New +$1.29M 0.72% 21

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Leap Investments's EBS Position: Q1 2020 in Review

Leap Investments sold out of Emergent Biosolutions (EBS) in Q1 2020, closing a stake of 10,100 shares — an estimated $545K sold.

Leap Investments first reported a position in EBS in Q3 2019 and held it in 2 quarters. The position peaked at $1.44M in Q3 2019. 263 funds tracked by Wall St. Rank hold EBS as of Q1 2020.

  • Leap Investments reported no remaining Emergent Biosolutions position as of Q1 2020 after selling out during the quarter.
  • Leap Investments sold 10,100 Emergent Biosolutions shares in Q1 2020, an estimated $545K.
  • Leap Investments first reported a position in Emergent Biosolutions in Q3 2019 and held it in 2 quarters.
  • Leap Investments's Emergent Biosolutions position peaked at $1.44M in Q3 2019.
  • 263 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.